Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Total Liabilities (2019 - 2025)

Historic Total Liabilities for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $55.0 million.

  • 4D Molecular Therapeutics' Total Liabilities rose 767.23% to $55.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.0 million, marking a year-over-year increase of 767.23%. This contributed to the annual value of $49.8 million for FY2024, which is 5525.54% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Total Liabilities of $55.0 million as of Q3 2025, which was up 767.23% from $52.7 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Total Liabilities high stood at $55.0 million for Q3 2025, and its period low was $14.3 million during Q2 2021.
  • For the 5-year period, 4D Molecular Therapeutics' Total Liabilities averaged around $33.9 million, with its median value being $30.5 million (2022).
  • In the last 5 years, 4D Molecular Therapeutics' Total Liabilities soared by 11289.89% in 2022 and then tumbled by 1196.74% in 2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Total Liabilities (Quarter) stood at $34.4 million in 2021, then fell by 11.26% to $30.5 million in 2022, then grew by 5.09% to $32.1 million in 2023, then soared by 55.26% to $49.8 million in 2024, then increased by 10.49% to $55.0 million in 2025.
  • Its Total Liabilities stands at $55.0 million for Q3 2025, versus $52.7 million for Q2 2025 and $46.0 million for Q1 2025.